An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.

ABSTRACT: Psoriatic arthritis is a complex and heterogeneous disease with potential significant disability and impaired quality of life. Although in the last decades new treatment options have led to a better management of this disease, there are still significant unmet therapeutic needs. Dual inhibitor antibodies target two different cytokines simultaneously, potentially offering a better disease control. In psoriatic arthritis, there is evidence for a pathogenic role not only of IL-17A but also the structurally homologous IL-17F. It is postulated that differential expression of both in several targets of PsA could account for disparities in clinical response to IL-17A inhibition alone (such as with secukinumab or ixekizumab). Here we review the evidence so far for the use in psoriatic arthritis of

SUBMITTER: Oliveira DG 

PROVIDER: S-EPMC7955739 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature